JP2018517731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517731A5 JP2018517731A5 JP2017564886A JP2017564886A JP2018517731A5 JP 2018517731 A5 JP2018517731 A5 JP 2018517731A5 JP 2017564886 A JP2017564886 A JP 2017564886A JP 2017564886 A JP2017564886 A JP 2017564886A JP 2018517731 A5 JP2018517731 A5 JP 2018517731A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- unsubstituted
- substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175510P | 2015-06-15 | 2015-06-15 | |
| US62/175,510 | 2015-06-15 | ||
| PCT/CN2016/085806 WO2016202253A1 (en) | 2015-06-15 | 2016-06-15 | Nrf2 regulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517731A JP2018517731A (ja) | 2018-07-05 |
| JP2018517731A5 true JP2018517731A5 (enExample) | 2020-11-12 |
| JP6789995B2 JP6789995B2 (ja) | 2020-11-25 |
Family
ID=57545504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564886A Active JP6789995B2 (ja) | 2015-06-15 | 2016-06-15 | Ｎｒｆ２レギュレーター |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10604509B2 (enExample) |
| EP (2) | EP3307739B1 (enExample) |
| JP (1) | JP6789995B2 (enExample) |
| KR (1) | KR102675041B1 (enExample) |
| CN (1) | CN108112251B (enExample) |
| AU (1) | AU2016279388B2 (enExample) |
| CA (1) | CA2988338C (enExample) |
| CL (1) | CL2017003226A1 (enExample) |
| CO (1) | CO2017012995A2 (enExample) |
| CY (1) | CY1123853T1 (enExample) |
| DK (2) | DK3307739T3 (enExample) |
| DO (1) | DOP2017000298A (enExample) |
| EA (1) | EA035864B1 (enExample) |
| ES (2) | ES2980945T3 (enExample) |
| FI (1) | FI3782996T3 (enExample) |
| HR (2) | HRP20240666T1 (enExample) |
| HU (2) | HUE066668T2 (enExample) |
| IL (1) | IL256297B (enExample) |
| LT (2) | LT3782996T (enExample) |
| MA (1) | MA52309B1 (enExample) |
| MX (1) | MX375352B (enExample) |
| MY (1) | MY207356A (enExample) |
| PE (1) | PE20180799A1 (enExample) |
| PH (1) | PH12017502255B1 (enExample) |
| PL (2) | PL3782996T3 (enExample) |
| PT (2) | PT3307739T (enExample) |
| RS (2) | RS61302B1 (enExample) |
| SI (2) | SI3307739T1 (enExample) |
| SM (1) | SMT202400207T1 (enExample) |
| WO (1) | WO2016202253A1 (enExample) |
| ZA (1) | ZA201708145B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180018684A (ko) | 2015-06-15 | 2018-02-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| JP2018529744A (ja) * | 2015-10-06 | 2018-10-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのアリールシクロヘキシルピラゾール |
| EP3359532A1 (en) | 2015-10-06 | 2018-08-15 | GlaxoSmithKline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| WO2018109647A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as nrf2 regulators |
| US20220002272A1 (en) * | 2016-12-14 | 2022-01-06 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl lactams as nrf2 activators |
| EP3555078B1 (en) | 2016-12-14 | 2024-03-27 | GlaxoSmithKline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 activators |
| ES2908941T3 (es) | 2016-12-15 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Triazoles unidos a éter como reguladores de NRF2 |
| US11028099B2 (en) * | 2016-12-15 | 2021-06-08 | Glaxosmithkline Intellectual Property Development Limited | NRF2 activators |
| CN119264073A (zh) * | 2017-05-17 | 2025-01-07 | 戴纳立制药公司 | 激酶抑制剂及其用途 |
| WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| JP7378156B2 (ja) * | 2018-04-06 | 2023-11-13 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | Ｋｅａｐ１／ｎｒｆ２タンパク質間相互作用の１，４－置換イソキノリン阻害剤 |
| AU2019326368B2 (en) | 2018-08-20 | 2021-11-11 | Janssen Pharmaceutica Nv | Inhibitors of KEAP1-Nrf2 protein-protein interaction |
| MX2021006527A (es) | 2018-12-05 | 2021-07-21 | Scohia Pharma Inc | Compuesto macrociclico y su uso. |
| KR102932313B1 (ko) | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
| AU2020283361B2 (en) * | 2019-05-31 | 2025-11-27 | Ube Corporation | Benzotriazole derivative |
| JP7583718B2 (ja) | 2019-07-03 | 2024-11-14 | 千寿製薬株式会社 | Ｎｒｆ２活性化化合物 |
| CN110845435B (zh) * | 2019-11-28 | 2021-06-08 | 中国药科大学 | 一种过氧化氢响应型Keap1-Nrf2 PPI抑制剂前药、制备方法及其医药用途 |
| KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
| KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
| CN114539085B (zh) * | 2020-11-26 | 2023-10-20 | 山东诚创蓝海医药科技有限公司 | 一种脲基衍生物的制备 |
| US20240132519A1 (en) | 2020-12-28 | 2024-04-25 | Senju Pharmaceutical Co., Ltd. | Nrf2-activating compound |
| TW202404984A (zh) * | 2022-04-28 | 2024-02-01 | 日商第一三共股份有限公司 | 苯并三唑化合物 |
| EP4516792A4 (en) * | 2022-04-28 | 2026-04-01 | Kyoto Pharma Ind | BENZOTHIOPHENE COMPOUND |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| NL192564C (nl) | 1982-10-08 | 1997-10-03 | Glaxo Group Ltd | Inrichting voor het toedienen van medicamenten aan patiënten. |
| EP0211595B1 (en) | 1985-07-30 | 1991-11-13 | Glaxo Group Limited | Devices for administering medicaments to patients |
| HU213221B (en) | 1990-03-02 | 1997-03-28 | Glaxo Group Ltd | Inhalation device and medicine packet for device |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| EP0570594B1 (en) | 1991-12-10 | 1997-07-30 | Shionogi & Co., Ltd. | Hydroxamic acid derivative based on aromatic sulfonamide |
| DE4220983A1 (de) * | 1992-06-26 | 1994-01-05 | Bayer Ag | Imidazolyl-substituierte Phenylpropion- und -zimtsäurederivate |
| CA2190870A1 (en) | 1994-05-27 | 1995-12-07 | George D. Hartman | Compounds for inhibiting osteoclast-mediated bone resorption |
| GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| MXPA03006666A (es) | 2001-01-25 | 2004-05-31 | Guilford Pharm Inc | Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso. |
| JPWO2002080899A1 (ja) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| EP1427415B1 (en) | 2001-09-21 | 2009-08-12 | Brystol-Myers Squibb Company | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| WO2004007464A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | イミダゾール誘導体 |
| CA2520804A1 (en) | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| WO2006044133A1 (en) | 2004-09-24 | 2006-04-27 | Axys Pharmaceuticals, Inc. | Active ketone inhibitors of tryptase |
| WO2006118320A1 (ja) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | チエノピリミドン化合物 |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| ES2436028T3 (es) | 2006-06-23 | 2013-12-26 | Radius Health, Inc. | Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno |
| CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
| MX2011000051A (es) | 2008-07-07 | 2011-07-28 | Fasgen Inc | Nuevos compuestos, composiciones farmaceuticas que contienen los mismos, metodos para usar los mismos, y metodos para preparar los mismos. |
| CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| US9382188B2 (en) | 2012-02-13 | 2016-07-05 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| WO2013155528A2 (en) | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
| WO2014145642A2 (en) * | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Nrf2 small molecule inhibitors for cancer therapy |
| BR112016014180A2 (pt) | 2013-12-18 | 2017-09-26 | Astex Therapeutics Ltd | reguladores de nrf2 |
| KR20180018684A (ko) | 2015-06-15 | 2018-02-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| KR20180017038A (ko) | 2015-06-15 | 2018-02-20 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| JP2018529744A (ja) | 2015-10-06 | 2018-10-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのアリールシクロヘキシルピラゾール |
| EP3359532A1 (en) | 2015-10-06 | 2018-08-15 | GlaxoSmithKline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
-
2016
- 2016-06-15 PH PH1/2017/502255A patent/PH12017502255B1/en unknown
- 2016-06-15 WO PCT/CN2016/085806 patent/WO2016202253A1/en not_active Ceased
- 2016-06-15 EA EA201890052A patent/EA035864B1/ru not_active IP Right Cessation
- 2016-06-15 JP JP2017564886A patent/JP6789995B2/ja active Active
- 2016-06-15 KR KR1020187000828A patent/KR102675041B1/ko active Active
- 2016-06-15 EP EP16810994.0A patent/EP3307739B1/en active Active
- 2016-06-15 MX MX2017016405A patent/MX375352B/es active IP Right Grant
- 2016-06-15 PT PT168109940T patent/PT3307739T/pt unknown
- 2016-06-15 CA CA2988338A patent/CA2988338C/en active Active
- 2016-06-15 EP EP20200207.7A patent/EP3782996B1/en active Active
- 2016-06-15 SI SI201631036T patent/SI3307739T1/sl unknown
- 2016-06-15 PL PL20200207.7T patent/PL3782996T3/pl unknown
- 2016-06-15 RS RS20210012A patent/RS61302B1/sr unknown
- 2016-06-15 PT PT202002077T patent/PT3782996T/pt unknown
- 2016-06-15 CN CN201680048338.1A patent/CN108112251B/zh active Active
- 2016-06-15 ES ES20200207T patent/ES2980945T3/es active Active
- 2016-06-15 SM SM20240207T patent/SMT202400207T1/it unknown
- 2016-06-15 AU AU2016279388A patent/AU2016279388B2/en active Active
- 2016-06-15 PL PL16810994T patent/PL3307739T3/pl unknown
- 2016-06-15 HR HRP20240666TT patent/HRP20240666T1/hr unknown
- 2016-06-15 HU HUE20200207A patent/HUE066668T2/hu unknown
- 2016-06-15 HR HRP20202036TT patent/HRP20202036T1/hr unknown
- 2016-06-15 RS RS20240608A patent/RS65562B1/sr unknown
- 2016-06-15 MA MA52309A patent/MA52309B1/fr unknown
- 2016-06-15 ES ES16810994T patent/ES2841574T3/es active Active
- 2016-06-15 PE PE2017002744A patent/PE20180799A1/es unknown
- 2016-06-15 US US15/736,075 patent/US10604509B2/en active Active
- 2016-06-15 HU HUE16810994A patent/HUE052919T2/hu unknown
- 2016-06-15 SI SI201631820T patent/SI3782996T1/sl unknown
- 2016-06-15 FI FIEP20200207.7T patent/FI3782996T3/fi active
- 2016-06-15 LT LTEP20200207.7T patent/LT3782996T/lt unknown
- 2016-06-15 LT LTEP16810994.0T patent/LT3307739T/lt unknown
- 2016-06-15 DK DK16810994.0T patent/DK3307739T3/da active
- 2016-06-15 DK DK20200207.7T patent/DK3782996T3/da active
- 2016-06-15 MY MYPI2017704768A patent/MY207356A/en unknown
-
2017
- 2017-11-30 ZA ZA2017/08145A patent/ZA201708145B/en unknown
- 2017-12-13 IL IL256297A patent/IL256297B/en active IP Right Grant
- 2017-12-15 CL CL2017003226A patent/CL2017003226A1/es unknown
- 2017-12-15 DO DO2017000298A patent/DOP2017000298A/es unknown
- 2017-12-19 CO CONC2017/0012995A patent/CO2017012995A2/es unknown
-
2019
- 2019-11-06 US US16/675,634 patent/US20200079759A1/en not_active Abandoned
-
2020
- 2020-12-29 CY CY20201101223T patent/CY1123853T1/el unknown
-
2021
- 2021-10-06 US US17/495,115 patent/US20230047296A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11912686B2 (en) | LPA receptor antagonists and uses thereof | |
| TWI541241B (zh) | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 | |
| US11713298B2 (en) | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid | |
| CN107849043B (zh) | 用于制备(4s)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-甲酰胺的方法 | |
| AU2014346919A1 (en) | Compositions and methods for modulating Farnesoid X receptors | |
| JP6444866B2 (ja) | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン及びその医薬として許容し得る形態の製造プロセス | |
| WO2018049068A1 (en) | N-acyl amino acid compounds and methods of use | |
| US10059677B2 (en) | Process for preparing phosphatidylinositol 3-kinase inhibitors and intermediates thereof | |
| JP2019532033A (ja) | オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 | |
| WO2021247215A1 (en) | Lpa receptor antagonists and uses thereof | |
| JP2022520442A (ja) | Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン | |
| KR102493943B1 (ko) | 포유류 티로신 키나제 ROR1 활성의 저해제로서 유용한 2-페닐-3H-이미다조[4,5-b]피리딘 유도체 | |
| JP2024525900A (ja) | グルカゴン様ペプチド－１受容体モジュレーター及びその使用 | |
| KR20180006450A (ko) | 우레아 유도체 또는 그의 약리학상 허용되는 염 | |
| JP6275881B2 (ja) | デュオカルマイシンのプロドラッグを製造するための改良された方法 | |
| JP2013521301A5 (enExample) | ||
| US11932631B2 (en) | Process for preparing aficamten | |
| WO2009007536A2 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| JP2008516935A (ja) | フェノキシベンズアミド化合物の製造方法 | |
| KR20160118359A (ko) | 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조 | |
| JP7406692B2 (ja) | 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法 | |
| AU2024359243A1 (en) | Processes for preparing kras inhibitors | |
| CN111936488A (zh) | 用于治疗寄生虫感染的新颖化合物 | |
| JP2001526257A (ja) | ナフタレン誘導体 | |
| US11104650B2 (en) | Process for production of 2-chloro-4-nitroimidazole derivatives |